Whether you're approaching the end of Phase II clinical development or planning for your regulatory submission, we can help you simplify the delivery of your human ADME studies.
Quotient Sciences' Synthesis-to-Clinic® approach pulls all the necessary elements required for the completion of a human ADME program together into a single, integrated program of work. We drive efficient development and manufacturing of 14C drug products tailored to the specific requirements of your ADME program — including intravenous (IV) products to generate IV pharmacokinetic and absolute bioavailability data, where appropriate.
Learn more about our expertise and capabilities in our whitepaper, Synthesis to Clinic: A streamlined approach to 14C human ADME studies.
“We conducted a 14C human ADME study with Quotient Sciences… We were extremely satisfied with all aspects of the study, including project management, formulation development, manufacture, clinical conduct, and reporting. We would use Quotient Sciences again for this type of study.”
-Oliver Schueller, SVP CMC and Clinical Pharmacology at Kadmon, a Sanofi Company
Iain Shaw is Senior Director of 14C Enabled Drug Development at Quotient Sciences. Iain has over 30 years of experience in the pharmaceutical industry, including more than 20 years of drug development experience and extensive experience with 14C human ADME studies.
Our team of experts have extensive chemical and radiochemical knowledge and experience of isotopically labeling hundreds of molecular entities.